In GBM, TAMs (both circulating macrophages and resident brain microglia) represent nearly half of the tumor mass [15], and the presence of CD68, a microglial marker, using a combination of tissue microarrays (TMA) and transcriptomic analyses, has been correlated with the clinical outcome of patients [16]. The gene discussed is CD68; the disease is glioblastoma.